Join Rapport Therapeutics for Their First Investor Day Event
Rapport Therapeutics, Inc. (NASDAQ: RAPP), a pioneering clinical-stage biotechnology company, is poised to welcome investors and analysts to its inaugural Investor and Analyst Day. This event is scheduled for a day that promises insightful discussions about groundbreaking advancements in the treatment of neurological and psychiatric disorders. Mark your calendars for this crucial gathering that aims to shed light on ongoing clinical programs and potential innovations in the field.
The Event: What to Expect
This exciting event will take place in New York City, bringing together key stakeholders from the health and investment communities. Senior management from Rapport Therapeutics will delve into the company’s robust clinical pipeline, highlighting pivotal trials such as the RAP-219 Phase 2a study focused on refractory focal epilepsy. This trial represents a significant step forward in the development of targeted treatments for patients who have not responded well to existing options.
Insights from Experts
A special highlight of the event will be a fireside chat featuring Dr. Jacqueline A. French, a renowned leader in the field of epilepsy research. As a professor of Neurology at NYU Langone's Comprehensive Epilepsy Center and the founder of the Epilepsy Study Consortium, Dr. French brings a wealth of knowledge and expertise that attendees will find invaluable. Joining her during this discussion will help attendees gain deeper insights into the nuances of epilepsy treatment and research.
Event Details
Attendees can expect a well-structured agenda, which will include:
- Date: An upcoming Monday in early June
- Time: Beginning at 3:00 PM and concluding by 5:00 PM Eastern Time
- Location: The event will be held at the Nasdaq MarketSite, a prominent venue for financial and corporate events.
For those unable to attend in person, the company will provide live and archived webcasts accessible through the Investors section of the Rapport Therapeutics website. This means that no one will miss out on the critical discussions and insights shared during the event.
About Rapport Therapeutics
Rapport Therapeutics specializes in the discovery and development of small molecule precision medicines aimed at treating neurological and psychiatric disorders. The company’s unique RAP technology platform is rooted in groundbreaking research concerning receptor-associated proteins (RAPs) in the brain. This foundational research guides Rapport's innovative approach to drug discovery, enabling the development of precision therapies that address unmet medical needs. Their leading candidate, RAP-219, exemplifies this targeted approach by selectively engaging with specific receptors in the brain, which is a significant advancement compared to conventional therapies.
In addition to RAP-219, which is being investigated for conditions like refractory focal epilepsy, bipolar mania, and diabetic peripheral neuropathic pain, Rapport is also advancing other programs aimed at chronic pain management and addressing hearing disorders. These initiatives showcase the company's commitment to broadening its impact within the neuroscience domain.
Contact Information
For inquiries or more information regarding the Investor Day or Rapport Therapeutics' programs, you can reach out to:
Julie DiCarlo
Head of Communications & IR, Rapport Therapeutics
jdicarlo@rapportrx.com
Frequently Asked Questions
What is the purpose of the Investor Day hosted by Rapport Therapeutics?
The Investor Day aims to provide insights into the company's clinical programs and advancements, fostering engagement with stakeholders.
Who will be speaking at the event?
Dr. Jacqueline A. French, a leading expert in epilepsy research, will participate in a fireside chat discussing key issues in the field.
When will the Investor Day take place?
The event is scheduled for early June, and specific details will be shared closer to the date.
Is there an option to view the event online?
Yes, the presentation will be webcast live and available for later viewing on the company's website.
What makes RAP-219 a significant development for patients?
RAP-219 offers targeted treatment for refractory focal epilepsy and shows promise for other neurological conditions, enhancing precision in care.
